Nexalin Technology (NASDAQ:NXL) Receives “Hold” Rating from Maxim Group

Maxim Group reaffirmed their hold rating on shares of Nexalin Technology (NASDAQ:NXL) in a research report report published on Thursday,Benzinga reports.

Nexalin Technology Trading Up 0.5 %

Shares of NXL opened at $4.17 on Thursday. The stock has a market cap of $53.63 million, a PE ratio of -6.52 and a beta of 3.78. Nexalin Technology has a 1 year low of $0.25 and a 1 year high of $4.49. The stock has a 50 day simple moving average of $2.52 and a 200-day simple moving average of $1.58.

Nexalin Technology (NASDAQ:NXL) last released its quarterly earnings results on Friday, November 8th. The company reported ($0.23) EPS for the quarter. The business had revenue of $0.04 million for the quarter. Nexalin Technology had a negative return on equity of 187.59% and a negative net margin of 3,407.98%.

Institutional Trading of Nexalin Technology

An institutional investor recently bought a new position in Nexalin Technology stock. CVI Holdings LLC purchased a new stake in Nexalin Technology, Inc. (NASDAQ:NXL) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 55,462 shares of the company’s stock, valued at approximately $94,000. CVI Holdings LLC owned 0.52% of Nexalin Technology at the end of the most recent reporting period. Institutional investors own 0.65% of the company’s stock.

Nexalin Technology Company Profile

Nexalin Technology, Inc, a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia.